Abstract：
Biologic therapies targeting tumor necrosis factor alpha (TNF-α) (infliximab, adalimumab, certolizumab, etanercept), the p40 subunit shared by IL-12 and IL-23 (ustekinumab), the p19 subunit of IL-23 (guselkumab, tildrakizumab, risankizumab), IL-17A (secukinumab, ixekizumab), IL-17-RA (brodalumab) and both IL-17A and IL-17F (bimekizumab) have revolutionized the treatment of psoriasis. In both the short and long term, risankizumab had highest Psoriasis Area and Severity Index 90 scores compared to other oral and injectable biologics. IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-α inhibitors.
摘要：
针对肿瘤坏死因子α（TNF-α）的生物疗法（英夫利昔单抗，阿达木单抗,赛托珠单抗，依那西普)，IL-12和IL-23共有的p40亚基（ustekinumab），IL-23的p19亚基(guselkumab，tildrakizumab，risankizumab)，IL-17A（苏金单抗，ixekizumab)，IL-17-RA（brodalumab）以及IL-17A和IL-17F（bimekizumab）都彻底改变了牛皮癣的治疗。无论是短期还是长期,与其他口服和可注射生物制剂相比,利沙珠单抗的银屑病面积和严重程度指数90分最高.与IL-17，IL-12/23和TNF-α抑制剂相比，IL-23抑制剂的短期和长期不良事件发生率最低，长期风险-效益最有利。
